You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Clinical and microbiological outcomes according to the antibiotic groups

From: Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli

  Piperacillin/tazobactam (N = 33) Cefepime (N = 6) Ertapenem (N = 33) p-value
Clinical success, n (%) 31 (93.9) 2 (33.3) 32 (97.0) <0.001
Microbiological success, n (%) 32 (97.0) 2 (33.3) 32 (97.0) <0.001
Clinical and microbiological success, n (%) 31 (93.9) 2 (33.3) 32 (97.0) <0.001
28-days mortality, n (%) 2 (6.1) 2 (33.3) 2 (6.1) 0.108